

**Benaroya Research Institute
IBC MEETING MINUTES
Thursday APRIL 02, 2026
12:00 AM - 01:00 PM
2 North Conference Room / Zoom**

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BSL: Biosafety Level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
RPD: Research Protections Department
BRI: Benaroya Research Institute
BSC: Biosafety Cabinet
SOP: Standard Operating Procedure

VOTING MEMBERS PRESENT:	Adam Lacy-Hulbert, PhD (<i>IBC Chair, Animal Containment Expert</i>) Estelle Bettelli, PhD (<i>Animal Containment Expert</i>) Bernard Khor, MD, PhD (<i>Affiliated Physician</i>) Ken Gordon (<i>Community Member</i>) Alison Cushman (<i>Community Member</i>) Andrew Burich, DVM (<i>Animal Containment Expert</i>) Alice Wiedeman, PhD (<i>Affiliated Member</i>)
ALTERNATE VOTING MEMBER(S) PRESENT:	None
VOTING MEMBERS ABSENT:	Shared seat: Angela Webb, RN (<i>Affiliated Member</i>) & Nadell Knee, MSN (<i>Affiliated Member</i>) Vivian Gersuk, PhD (<i>IBC Vice Chair</i>) Uma Malhotra, MD (<i>Affiliated Physician</i>) John Ray, PhD (<i>Affiliated Member</i>)
ADMINISTRATIVE SUPPORT:	Tessa Woods
OTHERS PRESENT:	Cheryl Weaver, BA, CCRC, CCRA Sarah Valenti, JD, CIP Vijaya Valiveti Annthea Vining Amir Figueroa, PhD

As of this meeting, the BRI IBC board has 12 active voting members, with one shared seat (11 seats total). To achieve quorum, at least 6 members are required to be present for voting (including experts as necessary).

1. Call to Order by the IBC Chair

For the purposes of voting today, Members were instructed that after each proposal in favor of passing to verbally confirm if in favor, by stating “aye.” Any member abstaining or voting against the proposal should identify himself or herself so the vote count can be accurate. The Chair will not check votes member by member, and if no abstentions or votes against a proposal are taken, the proposal will be assumed to have passed unanimously.

The IBC administrator took roll by recording the names of all attendees.

Estelle Bettelli left the meeting.

2. Confidentiality of Panel Proceedings

The members of the Benaroya IBC and the persons employed by the IBC were asked to maintain the confidentiality of the committee's proceedings unless such information was already made available to the public. The Parties shall maintain the confidentiality of the IBC's hearings, deliberations and initial report, and all written submissions to, and communications with, the IBC.

Estelle Bettelli returned to the meeting.

3. Conflict of Interest Notice

The Chair reminded committee members of Virginia Mason Health Systems policies regarding conflict of interest and asked that any member who might have a conflict of interest make it known and abstain from the vote.

4. Review of Draft Minutes from the Previous Meeting**A. January 29, 2026 IBC Meeting Minutes**

IBC Decision and Vote				
A motion was made to approve the meeting minutes as presented. The motion was seconded.				
For: 6	Against: 0	Abstained: 1	Absent: 4	Recused: 0

5. Safety Update

A. Injury Exposure Report, Incident Date 03/18/2025

Submitted: 03/18/2025		
Description:	The Safety team was notified by an employee of a spill involving mouse and human cell samples in the 4th floor autoclave. The spill or leak was discovered after the autoclave cycle had been completed. No injuries were reported in connection with the incident. The employee was uncertain whether the spill should be treated as a hazardous material spill and contacted Safety for guidance on appropriate cleanup procedures.	
VM Employee Health Consulted: N/A	Medical Treatment Required: Not required	Time off expected: Not required
Preventative/Corrective Action:	The BRI Safety team assessed the situation and advised the employee to disinfect the interior of the autoclave using an approved disinfectant. The employee was also instructed to verify that the chemical integrator indicated successful sterilization and to confirm that the sterilization cycle had been completed. Additionally, the Safety and Facilities teams will collaborate to develop an informational guide outlining procedures for handling spills and disinfection process in autoclaves. Please let me know if you have any questions or need more information on this.	
Discussion:	There have been issues with autoclaves requiring repair. Safety continues to monitor and address the issue. There are parts required for repair that we are still waiting for. The board questioned how old the autoclaves are. The board discussed the necessity of autoclaving. The board also discussed the need to refresh staff on how to bag up the materials used in the autoclave. Safety confirmed that they will continue to address these issues and follow up with the necessary parties as appropriate.	

6. Notification of Administrative Action (01/16/2025 – 03/16/2026)

A. Protocol ID: IBC22-052, Continuing Review

PI	Title	BSL	NIH Guidelines
Picozzi, Vincent	A Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in Patients with KRAS G12D/G12V Mutated Pancreatic Ductal Adenocarcinoma	1, 2	III-D
Additional Safety Practices:	n/a		
Primary Reviewer(s):	Lacy-Hulbert, Adam		
Summary:	Updates were made to personnel. Biosafety training is up to date. Treatment cards and information sheets are available to staff.		
Approved on: 02/17/2026			

B. Protocol ID: IBC24-013, Amendment

PI	Title	BSL	NIH Guidelines
Campbell, Daniel	Cell and Tissue Analysis Core Facility	1, 2	III-D, III-E
Additional Safety Practices:	Individual labs must provide specific risk assessments pertaining to their protocols. Any risk assessments above BSL1 must be communicated and agreed with the facility staff.		
Summary:	Updates were made to personnel. Biosafety training is up to date. Treatment cards and information sheets are available to staff.		
Approved on: 02/17/2026			

C. Protocol ID: IBC23-049, Continuing Review

PI	Title	BSL	NIH Guidelines
James, Eddie	Study of the interface between immune cells (derived from human blood or tissue) and their target tissues	2	III-D, III-E
Additional Safety Practices:	Live cell sorting will require additional safety practices.		
Primary Reviewer(s):	Lacy-Hulbert, Adam		
Summary:	Updates were made to personnel. Biosafety training is up to date. Treatment cards and information sheets are available to staff.		

Approved on: 03/10/2026

7. New Business

A. Protocol ID: IBC26-003, Three-year Renewal

PI	Title	BSL	NIH Guidelines
Mikacenic, Carmen	Human Immune Responses in the Blood and Lung	1, 2	III-E
Additional Safety Practices:	n/a		
Recused:	n/a		
Discussion:	The primary reviewers provided the IBC with an overview of the protocol, its design, and its aims. The Application included additional biohazards and their proposed containment levels. - The Committee reviewed the application, conducted a risk assessment, and determined the biocontainment levels for the research proposed met all applicable NIH Guidelines. - The Committee confirmed the facilities, procedures, practices, training and expertise of personnel are adequate for safe work with all biohazards listed. - Biosafety training updates are required. - Treatment cards and information sheets are available to staff.		
Decision:	The IBC discussed the criteria for approval and required the following modifications: - Minor revisions to the application as outlined in eProtocol comments and per discussion. - Training must be renewed for the relevant study personnel		

IBC Decision and Vote				
A motion was made to approve the protocol after the modifications mentioned in the meeting and in eProtocol are met. The motion was seconded.				
For: 7	Against: 0	Abstained: 0	Absent: 4	Recused: 0

B. Protocol ID: IBC26-004, Three-year Renewal

PI	Title	BSL	NIH Guidelines
Lord, Sandra	Conducting Research Data and Specimen Collection Activities in the BRI Building	2	n/a

Additional Safety Practices:	n/a
Recused:	n/a
Discussion:	The primary reviewers provided the IBC with an overview of the protocol, its design, and its aims. The Application included additional biohazards and their proposed containment levels. • The Committee reviewed the application, conducted a risk assessment, and determined the biocontainment levels for the research proposed met all applicable NIH Guidelines. • The Committee confirmed the facilities, procedures, practices, training and expertise of personnel are adequate for safe work with all biohazards listed. ○ Biosafety training updates are required. ○ Treatment cards and information sheets are available to staff.
Decision:	The IBC discussed the criteria for approval and determined that due to the revisions, the protocol may not be required anymore. The board discussed tabling the item, and IBC Admin will reach out to the PI to confirm if this protocol needs to be closed.

IBC Decision and Vote				
A motion was made to table the submission. The motion was seconded.				
For: 7	Against: 0	Abstained: 0	Absent: 4	Recused: 0

C. Protocol ID: IBC26-001, Vote to Extend Expiration of Protocol

PI	Title	BSL	NIH Guidelines
Ziegler, Steven	Regulation of Immunity and Inflammation	1, 2	III-D, III-E
Additional Safety Practices:	n/a		
Recused:	n/a		
Discussion:	This protocol requires a vote to extend the expiration date to June 01, 2026. Additional time is needed to address upcoming staffing changes. Following this meeting, the protocol will be assessed for potential review at the May 28, 2026 meeting.		

Decision:	The IBC discussed granting the protocol an extension to June 01, 2026. Safety will continue to discuss disposal of biohazards with the lab.
------------------	---

IBC Decision and Vote				
A motion was made to approve the protocol after the modifications mentioned in the meeting and in eProtocol are met. The motion was seconded.				
For: 7	Against: 0	Abstained: 0	Absent: 4	Recused: 0

D. Protocol ID: IBC23-008, Vote to Extend Expiration of Protocol

PI	Title	BSL	NIH Guidelines
Long, Alice	Human Immunophenotyping Core	1, 2	III-E
Additional Safety Practices:	n/a		
Recused:	Wiedeman, Alice		
Discussion:	This protocol requires a vote to extend the expiration date to June 01, 2026. Additional time is needed to address upcoming staffing changes. Following this meeting, the protocol will be assessed for potential review at the May 28, 2026 meeting.		
Decision:	This protocol requires a vote to extend the expiration date to June 01, 2026. Following this meeting, the protocol will be assessed for potential review at the May 28, 2026 meeting.		

Alice Wiedeman left the meeting due to a conflict of interest.

IBC Decision and Vote				
A motion was made to approve the protocol after the modifications mentioned in the meeting and in eProtocol are met. The motion was seconded.				
For: 6	Against: 0	Abstained: 0	Absent: 4	Recused: 1

Alice Wiedeman returned to the meeting.

8. Discussion Items

A. Update on Cayuse Transition

Title		Voting Requirement
n/a		No vote required
Discussion:	IBC Admin gave the board a brief update on the transition from eProtocol to Cayuse systems. IBC Admin anticipated transitioning the board to Cayuse between June and August 2026. The board will be given will be given the appropriate training.	

9. Adjournment

Next meeting May 28, 2026, 11:00am, 4 North Conference Room / Zoom


 box SIGN 31RJ7L1W-13RK5QRW

Adam Lacy-Hulbert, PhD
IBC Chair

Jul 24, 2026

Date

Prepared by:


 box SIGN 21XY6L4Y-13RK5QRW

Tessa Woods
Regulatory Specialist II

Jul 24, 2026

Date

ecc: Jane Buckner, MD, BRI President
 Margaret McCormick, PhD, BRI Institutional Official
 Cheryl Weaver, BA, CCRC, CCRA, Director of Research Integrity & Safety
 Adam Lacy-Hulbert, PhD, IBC Chair
 IBC Office File